Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer

Several lines of preclinical evidence indicate that combining PI3K and CDK4/6 inhibitors may further enhance the efficacy of hormonal therapy by overcoming de novo and acquired resistance to PI3K and CDK4/6 blockade. We evaluated the combination of abemaciclib, letrozole and LY3023414 (an orally ava...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Panagiotis A. Konstantinopoulos, Niya Xiong, Carolyn Krasner, Joyce F. Liu, Hannah Sawyer, Madeline Polak, Hope Needham, Megan Geddes, Lani Koppermann, Meghan Shea, Cesar Castro, Su-Chun Cheng, Ursula A. Matulonis, Elizabeth K. Lee
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2024-04-01
Serie:	Gynecologic Oncology Reports
Soggetti:	Abemaciclib Aromatase inhibition CDK4/6 inhibition PI3K inhibition LY3023414 Endometrial cancer
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2352578924000274
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!